Every 8-K that Adverum Biotechnologies, Inc. (ADVM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ADVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADVM filings page.
Adverum Biotechnologies, Inc. reported the early termination of its lease for facilities at 14 TW Alexander Drive in Durham, North Carolina, and the creation of a related financial obligation. The landlord ended the lease effective November 19, 2025, even though the term had originally been set to run through October 2037. As consideration, Adverum agreed to pay $0.1 million in cash within 30 days of receiving the termination notice and to release a previously escrowed $7.4 million promissory note to the landlord, with a maturity date on the earlier of January 31, 2031 or the company reaching $150 million in annual net revenues or royalties from its lead gene therapy candidate, Ixo-vec, and subject to acceleration upon a change of control. Adverum also disclosed that it has completed target enrollment of 284 patients in its pivotal Phase 3 ARTEMIS trial of Ixo-vec as of November 19, 2025, marking an important clinical development milestone.
Adverum Biotechnologies agreed to be acquired by Eli Lilly via a tender offer and follow-on merger. Holders will receive $3.56 in cash per share plus one non‑tradable CVR with potential milestone payments of up to $8.91 per CVR, subject to specified regulatory and commercial milestones for the Ixo‑vec product.
The offer requires a majority of outstanding shares to be tendered and is followed by a merger under DGCL Section 251(h) without a stockholder vote. The board unanimously approved the deal and recommends stockholders tender. The agreement permits a $4,000,000 termination fee in specified circumstances and includes customary non‑solicitation terms and conditions.
Concurrently, Lilly provided up to $65.0 million in secured financing via a note with scheduled advances ($5.0M on Oct 28; $15.0M on Nov 7; $20.0M on Nov 21; $25.0M on Dec 5), interest at SOFR + 10.0%, maturity on January 22, 2026, a 5.0% prepayment premium, and a first‑priority lien. The filing also details treatment of equity awards, including 1,959,880 PSUs becoming effective, and outlines warrant treatment at closing.
Adverum Biotechnologies, Inc. filed a current report describing updated timelines for its pivotal Phase 3 ARTEMIS trial evaluating Ixo-vec in wet age-related macular degeneration. The company plans to complete screening for the ARTEMIS trial this month and now anticipates full enrollment in the fourth quarter of 2025. It expects to announce topline data from this Phase 3 study in the first quarter of 2027, giving a clear view of when key clinical results may become available. The report also notes that these statements are forward-looking and subject to significant risks and uncertainties, and that additional risk factors are discussed in the company’s periodic SEC reports.
Adverum Biotechnologies reported that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1, and the cover page of the report is presented in Inline XBRL as Exhibit 104.
The filing explicitly states that the information in the report and the exhibit is not deemed "filed" under the Exchange Act and will not be incorporated by reference into other SEC filings. The 8-K itself does not include the underlying financial figures; the detailed results are contained in the furnished press release.